Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma—a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology

Marvaso, Giulia; Jereczek-Fossa, Barbara Alicja; Zaffaroni, Mattia; Vincini, Maria Giulia; Corrao, Giulia; Andratschke, Nicolaus; Balagamwala, Ehsan H; Bedke, Jens; Blanck, Oliver; Capitanio, Umberto; Correa, Rohann J M; De Meerleer, Gert; Franzese, Ciro; Gaeta, Aurora; Gandini, Sara; Garibaldi, Cristina; Gerszten, Peter C; Gillessen, Silke; Grubb, William R; Guckenberger, Matthias; Hannan, Raquibul; Jhaveri, Pavan M; Josipovic, Mirjana; Kerkmeijer, Linda G W; Lehrer, Eric J; Lindskog, Magnus; Louie, Alexander V; Nguyen, Quynh-Nhu; Ost, Piet; Palma, David A; Procopio, Giuseppe; Rossi, Maddalena; Staehler, Michael; Tree, Alison C; Tsang, Yat Man; Van As, Nicholas; Zaorsky, Nicholas G; Zilli, Thomas; Pasquier, David; Siva, Shankar

doi:10.1016/s1470-2045(24)00023-8

The Lancet Oncology

2024

DOI: 10.1016/s1470-2045(24)00023-8

|View full text |Cite

Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma—a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology

Giulia Marvaso,

Barbara Alicja Jereczek-Fossa,

Mattia Zaffaroni

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 8 publications

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

War of skeleton defense: the protection of bone in the process of tumor treatment

Xu,

Tang

2024

Holist Integ Oncol

View full text Add to dashboard Cite

Bone health and maintenance of integrity are essential aspects for cancer patients receiving comprehensive treatment. With the breakthrough in different cancer therapies, the number of long-term cancer survivors is rapidly expanding. At the same time, the bone health issues are gradually becoming more serious. This commentary aims to summarize the bone damage derived from tumor itself, cancer bone metastases and cancer therapies, including chemotherapy, radiotherapy, endocrine therapy, immune therapy and to highlight strategies for protecting the skeleton.

show abstract

War of skeleton defense: the protection of bone in the process of tumor treatment

Xu,

Tang

2024

Holist Integ Oncol

View full text Add to dashboard Cite

show abstract

Survival Without Quality of Life Deterioration in the GORTEC 2014-04 “OMET” Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR

Thariat,

Bosset,

Falcoz

et al. 2024

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Current State of Stereotactic Body Radiation Therapy for Genitourinary Malignancies

Sherry,

Desai,

Tang

2024

Cancer J

View full text Add to dashboard Cite

Stereotactic body radiation therapy (SBRT) involves the delivery of high-dose, highly precise radiation therapy to focal sites of gross tumor involvement. Recent advances in radiation planning and image guidance have facilitated rapid growth in the evidence for and use of SBRT, particularly for genitourinary malignancies, where the underlying radiobiology often suggests greater tumor sensitivity to SBRT than to conventionally fractionated radiation. Here, we review the evolution of SBRT for patients with prostate adenocarcinoma and renal cell carcinoma. We discuss state-of-the-art trials, indications, and future directions in the SBRT-based management of both localized and metastatic disease. With rapidly growing enthusiasm and evidence, clinical and translational research efforts on the biology and outcomes of SBRT over the coming decade will be crucial to refining the indications, technical approach, and synergistic combinations of SBRT with highly active systemic therapies and improve the efficacy and quality-of-life outcomes for patients with genitourinary malignancies.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma—a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology

Cited by 8 publications

References 39 publications

War of skeleton defense: the protection of bone in the process of tumor treatment

War of skeleton defense: the protection of bone in the process of tumor treatment

Survival Without Quality of Life Deterioration in the GORTEC 2014-04 “OMET” Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR

Current State of Stereotactic Body Radiation Therapy for Genitourinary Malignancies

Contact Info

Product

Resources

About